Editorial: Evaluating the Prevalence of Metabolic Dysfunction‐Associated Steatotic Liver Disease in Patients With Type 2 Diabetes and Hyperferritinaemia—Authors' Reply

Documenti analoghi

• A Prospective Study on the Prevalence of MASLD in Patients With Type 2 Diabetes and Hyperferritinaemia
  di: Maral Amangurbanova, et al.
  Pubblicazione: (2024)
• Editorial: Revolutionising Steatotic Liver Disease Diagnosis With Phosphatidylethanol—Authors' Reply
  di: Federica Tavaglione, et al.
  Pubblicazione: (2025)
• Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality
  di: Donghee Kim, et al.
  Pubblicazione: (2025)
• Letter: Safety and Tolerability of Injectable Extended‐Release Naltrexone for the Management of Alcohol Use Disorder in Advanced Alcohol‐Associated Liver Disease—Authors' Reply
  di: Luis Antonio Díaz, et al.
  Pubblicazione: (2025)
• Editorial: Comparable Hepatic Fibrosis Risk Demands Equal Vigilance in Lean and Non‐Lean Patients With Metabolic Dysfunction‐Associated Steatotic Liver Disease—Authors' Reply
  di: Kaleb Tesfai, et al.
  Pubblicazione: (2025)